GR1006896B - Μεθοδος παραγωγης μιας πεπτιδικης ορμονης - Google Patents

Μεθοδος παραγωγης μιας πεπτιδικης ορμονης

Info

Publication number
GR1006896B
GR1006896B GR20070100553A GR20070100553A GR1006896B GR 1006896 B GR1006896 B GR 1006896B GR 20070100553 A GR20070100553 A GR 20070100553A GR 20070100553 A GR20070100553 A GR 20070100553A GR 1006896 B GR1006896 B GR 1006896B
Authority
GR
Greece
Prior art keywords
producing
peptide hormone
hepcidin
novel
provides
Prior art date
Application number
GR20070100553A
Other languages
English (en)
Other versions
GR20070100553A (el
Inventor
Αυγη Μαμαλακη
Βασιλικη Κολιαρακη
Μαρθα Μαρινου
Original Assignee
Ελληνικο Ινστιτουτο Παστερ,
Αυγη Μαμαλακη
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ελληνικο Ινστιτουτο Παστερ,, Αυγη Μαμαλακη filed Critical Ελληνικο Ινστιτουτο Παστερ,
Priority to GR20070100553A priority Critical patent/GR1006896B/el
Priority to CA2697976A priority patent/CA2697976A1/en
Priority to EP08788798A priority patent/EP2195339A2/en
Priority to KR1020107006382A priority patent/KR20100065335A/ko
Priority to US12/675,007 priority patent/US8614068B2/en
Priority to JP2010521489A priority patent/JP2010536364A/ja
Priority to PCT/GR2008/000056 priority patent/WO2009027752A2/en
Priority to AU2008291842A priority patent/AU2008291842A1/en
Publication of GR20070100553A publication Critical patent/GR20070100553A/el
Publication of GR1006896B publication Critical patent/GR1006896B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μια καινοτόμο μέθοδο για παραγωγή βιολογικά λειτουργικής εψιδίνης. Η εφεύρεση παρέχει νέα σημασμένη εψιδίνη, αντισώματα και τη χρήση τους στην θεραπεία και σε ανοσοδοκιμασίες.
GR20070100553A 2007-08-24 2007-08-24 Μεθοδος παραγωγης μιας πεπτιδικης ορμονης GR1006896B (el)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GR20070100553A GR1006896B (el) 2007-08-24 2007-08-24 Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
CA2697976A CA2697976A1 (en) 2007-08-24 2008-08-22 A process for producing a peptide hormone
EP08788798A EP2195339A2 (en) 2007-08-24 2008-08-22 A process for producing hepcidin
KR1020107006382A KR20100065335A (ko) 2007-08-24 2008-08-22 헵시딘을 제조하는 방법
US12/675,007 US8614068B2 (en) 2007-08-24 2008-08-22 Process for producing hepcidin
JP2010521489A JP2010536364A (ja) 2007-08-24 2008-08-22 ペプチドホルモンの生成工程
PCT/GR2008/000056 WO2009027752A2 (en) 2007-08-24 2008-08-22 Process for producing hepcidin
AU2008291842A AU2008291842A1 (en) 2007-08-24 2008-08-22 Process for producing hepcidin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20070100553A GR1006896B (el) 2007-08-24 2007-08-24 Μεθοδος παραγωγης μιας πεπτιδικης ορμονης

Publications (2)

Publication Number Publication Date
GR20070100553A GR20070100553A (el) 2009-03-17
GR1006896B true GR1006896B (el) 2010-07-20

Family

ID=40219993

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20070100553A GR1006896B (el) 2007-08-24 2007-08-24 Μεθοδος παραγωγης μιας πεπτιδικης ορμονης

Country Status (8)

Country Link
US (1) US8614068B2 (el)
EP (1) EP2195339A2 (el)
JP (1) JP2010536364A (el)
KR (1) KR20100065335A (el)
AU (1) AU2008291842A1 (el)
CA (1) CA2697976A1 (el)
GR (1) GR1006896B (el)
WO (1) WO2009027752A2 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609817B2 (en) 2008-08-06 2013-12-17 Eli Lilly And Company Anti-hepcidin-25 selective antibodies and uses thereof
BR112012003701A2 (pt) 2009-08-20 2019-09-24 Vifor Int Ag "novos antagonistas de quinolina-hepcidina"
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
BR112012005119A2 (pt) 2009-09-07 2016-11-22 Vifor Int Ag novos antagonistas de hepcidina etanodiaminas
AR078278A1 (es) 2009-09-09 2011-10-26 Vifor Int Ag Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
KR102236829B1 (ko) * 2013-03-15 2021-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 헵시딘 유사체 및 이의 용도
AU2015258863B2 (en) 2014-05-16 2019-10-24 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
WO2015200916A2 (en) * 2014-06-27 2015-12-30 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
AU2015289642B2 (en) 2014-07-17 2021-02-25 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3432906A4 (en) 2016-03-23 2020-04-01 Protagonist Therapeutics, Inc. METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS
WO2018187548A2 (en) * 2017-04-05 2018-10-11 Arizona Board Of Regents On Behalf Of Arizona State University Antimicrobial susceptibility testing with large-volume light scattering imaging and deep learning video microscopy
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
TW202019948A (zh) 2018-07-12 2020-06-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其治療發炎疾病之用途
CN109593766A (zh) * 2018-12-11 2019-04-09 武汉大北农水产科技有限公司 草鱼铁调素基因及其编码的重组蛋白和应用
MX2022000397A (es) 2019-07-10 2022-04-25 Protagonist Therapeutics Inc Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
CN118063554A (zh) 2020-01-15 2024-05-24 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
KR20220141808A (ko) 2020-01-15 2022-10-20 얀센 바이오테크 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
TW202330013A (zh) 2021-07-14 2023-08-01 美商健生生物科技公司 介白素－２３受體之脂化肽抑制劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
AU2003295644A1 (en) 2002-11-19 2004-07-22 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin

Also Published As

Publication number Publication date
WO2009027752A3 (en) 2009-06-11
US8614068B2 (en) 2013-12-24
AU2008291842A1 (en) 2009-03-05
GR20070100553A (el) 2009-03-17
WO2009027752A2 (en) 2009-03-05
US20110097749A1 (en) 2011-04-28
EP2195339A2 (en) 2010-06-16
CA2697976A1 (en) 2009-03-05
KR20100065335A (ko) 2010-06-16
JP2010536364A (ja) 2010-12-02

Similar Documents

Publication Publication Date Title
GR20070100553A (el) Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
MY148763A (en) Anti-5t4 antibodies and uses thereof
TW200616662A (en) Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
MY171841A (en) Antibody formulation
EP1814586A4 (en) ANTI-PROPERDINE ANTIBODY AND METHOD OF MANUFACTURING AND USING THE SAME
SG162728A1 (en) Tweak binding antibodies
TW200738270A (en) Method of treating depression using a TNFα antibody
PE20150222A1 (es) Anticuerpos multiespecificos
WO2009004822A1 (ja) 抗Muc17抗体
SG170793A1 (en) Anti-mn antibodies and methods of using same
WO2010145792A8 (en) Bispecific antigen binding proteins
WO2008053330A3 (en) Monoclonal antibodies against the human anti-mullerian hormone type ii receptor (amhr-ii)
PL1963368T6 (pl) Przeciwciała anty-IL-17
SG10201600950TA (en) Recombinant monovalent antibodies and methods for production thereof
SG166091A1 (en) Method for producing isocyanates
MX2007002675A (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
TW200636064A (en) Anti-respiratory syncytial virus antibodies, antigens and uses thereof
MY183144A (en) Toll-like receptor 3 antagonists
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
EP1940864A4 (en) PROCESS FOR GENERATING MONOCLONAL ANTIBODIES WITH A VIVO REGION
WO2010079510A3 (en) Anti-rhd monoclonal antibodies
MY180699A (en) Toll-like receptor 3 antagonists
MY150643A (en) Methods and compositions for targeting hepsin
WO2005049652A3 (en) Methods of generating antibody diversity in vitro

Legal Events

Date Code Title Description
PG Patent granted